Don't wait for the scan. Stay months ahead of the cancer.
The traditional approach to cancer monitoring is terrifyingly reactive: wait 3 to 6 months, get a PET scan, and hope.
But by the time a tumour is large enough to physically appear on a scan, the cancer has already gained dangerous momentum.
Onkommon Sentinel is an ultra-sensitive, continuous molecular surveillance program. By regularly testing your blood at the microscopic level, we track the cancer's DNA in real-time. If the cancer begins to return, or if it mutates to resist your current drug, Sentinel detects it 3 to 12 months before any physical symptoms appear and before any scan can see it.
We alert your oncologist the moment the cancer changes at a cellular level, giving them the ultimate clinical advantage: the time to pivot your treatment and outsmart the disease before it takes hold.
Molecular surveillance that outpaces the disease.
Sentinel tracks your cancer's DNA in real-time — catching recurrence or resistance months before scans or symptoms.
- Ultra-Sensitive: Detects 1 cancer cell in 100,000 healthy cells
- Real-Time Tracking: Regular blood draws monitor ctDNA levels
- Early Warning: 3–12 months ahead of physical symptoms
- Actionable Alerts: Your oncologist is briefed immediately
- Blueprint Care Bundled: Full coordination support included
The problem with waiting.
Why standard imaging is not enough for proactive cancer management.
The PET/CT Scan Limit
Standard imaging looks for physical masses. A scanner typically cannot definitively detect cancer until a tumour is about 1 centimetre in size. A 1-centimetre tumour can contain hundreds of millions of active cancer cells. Waiting for a scan means waiting for the cancer to win ground.
⚠️ Detects only after masses formThe Sentinel ctDNA Advantage
As cancer cells multiply or die, they shed microscopic fragments of their DNA — known as Circulating Tumour DNA (ctDNA) — into your bloodstream. Sentinel is a highly advanced Liquid Biopsy MRD tracker. We extract this free-floating DNA from a simple blood draw. Our sequencing is so sensitive it can detect a single cancer cell hiding among 100,000 healthy blood cells.
✅ Detects the molecular sparkThe mandatory baseline.
We cannot track an enemy we have never seen.
CRITICAL NOTE: You cannot enter the Sentinel continuous monitoring program without first establishing your tumour's unique molecular fingerprint.
Before you can begin Sentinel, you must have an Onkommon Signature Baseline (118-gene) test on file (or a qualifying Complete CGP 523-gene test). This initial blood test or tissue biopsy maps the exact driver mutations unique to your specific cancer.
Every subsequent Sentinel blood draw you take is computationally compared against this initial Baseline. We look precisely at the specific mutations we know belong to your tumour to see if their Variant Allele Frequency (VAF) is rising or falling.
Start with Signature Baseline
Establish your tumour's molecular fingerprint with our 118-gene comprehensive genomic profiling test.
Learn More About Signature BaselineSurveillance tiers.
We offer three tiers of continuous surveillance, tailored precisely to your current stage of treatment and clinical risk.
Sentinel Lite
- The Goal: Pure peace of mind. Replacing "scan anxiety" with molecular certainty.
- How it Works: Routine, highly sensitive blood draws designed exclusively to confirm the cancer remains completely gone (MRD Negative), or to catch a silent relapse at the microscopic level months before physical symptoms occur.
Sentinel Core
- The Goal: Catching drug resistance before the tumour physically grows.
- How it Works: Frequent blood draws (typically every 6 to 8 weeks) tracking the specific mutations driving your cancer. If we see a "resistance mutation" begin to rise in your blood, we instantly alert your oncologist so they can switch your therapy before the cancer spreads.
Sentinel Plus
- The Goal: Relentless, elite-level clinical management and proactive trial hunting.
- How it Works: The maximum frequency of molecular blood draws (up to 8 per year), featuring an Annual KCCIRC Multidisciplinary Tumour Board Review to comprehensively map the next phase of your survival strategy.
What happens when we find something?
You are never left alone with bad news. Sentinel is backed by an active clinical response team.
The Red Flag
Our AI and clinical team detect a rising Variant Allele Frequency (VAF) or a new resistance mutation.
The Immediate Briefing
Your dedicated Care Coordinator contacts you and your treating oncologist immediately. We do not wait for your next scheduled appointment.
The Counter-Attack Plan
Our clinical intelligence team instantly cross-references this newly detected resistance mutation against global databases to find the specific next-line therapies, compassionate access drugs, or active clinical trials designed to defeat it.
Seamless Transition
We handle the logistics of altering your Patient Assistance Programs (PAPs) and booking your urgent hospital visits to get you onto the new therapy rapidly.
Adapting to your cancer.
Sentinel is not a one-size-fits-all test. The laboratory protocol changes based on the biology of your specific disease.
Solid Tumour Sentinel
Utilizes our advanced 107-gene ctDNA MRD liquid biopsy panel to track solid mass shedding in the blood (e.g., Lung, Breast, Colon, Prostate).
107-gene ctDNA panelBlood Cancer Sentinel
In Leukaemia, Lymphoma, and Myeloma, standard monitoring isn't enough. We utilize the precise protocol mandated by your initial Signature Stratification result. We use NPM1 quantitative PCR (hyper-fast 3-day result) for NPM1+ AML, B-cell clonality NGS for Lymphoma/CLL, and Fusion Tracking for BCR-ABL1 (CML or Ph+ ALL).
PCR · NGS · Fusion trackingThe Blueprint Care bundle.
Continuous data requires continuous human support.
Dedicated Care Coordinator
While the laboratory tracks your DNA, your dedicated Care Coordinator tracks you — weekly check-ins, in-person meetings, and full logistical support.
Financial Shield (PAP Management)
All of your complex PAP (financial assistance) applications are managed entirely by our team for the entire year you are on Sentinel.
Clinical Trial & Access Hunting
Continuous monitoring of CTRI and global databases for new trials, compassionate access routes, and repurposed drugs relevant to your evolving cancer profile.
KCCIRC Clinic Wing
While Onkommon Sentinel provides your current treating doctor with real-time molecular surveillance, we understand that an unexpected rise in your ctDNA might prompt you to seek a new medical perspective.
If Sentinel detects recurrence or resistance and you require a formal, medical second opinion on how to alter your treatment, Onkommon is proud to partner directly with the KCCIRC Clinic Wing.
You can choose to seamlessly transition your Sentinel molecular data to the KCCIRC multidisciplinary tumour board for a formal clinical review and a direct treatment prescription.
Please note: A formal medical consultation with KCCIRC doctors is a separate clinical service billed in addition to your Sentinel subscription.
KCCIRC Multidisciplinary Tumour Board
Led by senior oncologists, our tumour board reviews complex molecular surveillance data with the full weight of clinical expertise — delivering a formal written opinion on your next treatment steps.
Delhi & SikkimFrequently Asked Questions
Everything you need to know about Sentinel Continuous Monitoring.
No. Sentinel is designed to be used in conjunction with standard imaging as requested by your oncologist. While Sentinel can detect cancer much earlier than a scan, standard imaging is still required by global guidelines to locate exactly where the cancer is physically residing in the body.
Sentinel is frequent, highly targeted monitoring looking specifically at the mutations we already know your tumour has, catching resistance early. Track is a broad, comprehensive 118-gene re-profiling done at major clinical milestones (like every 6 months) to see if the cancer has developed entirely new mutations that a targeted test might miss. Often, patients use a combination of both.
Cancer biology is not static; it constantly changes. A one-time test only shows us what the cancer looked like on that specific day. Sentinel is an ongoing subscription because monitoring must be continuous to catch the exact moment the cancer mutates or tries to return.
Yes. While Sentinel is an annual clinical commitment (as tracking must occur over a long period to be effective), we offer structured EMI options (e.g., ₹40,000/month for Sentinel Core) to make the financial impact manageable for families.